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A new and direct colorimetric method has been established for the determination of catecholamine (methyldopa, MD) in 
both pure form and in pharmaceutical formulations. The method is based on the oxidative coupling reaction of MD with 
3-methyl-2-benzothiazolinone hydrazone hydrochloride monohydrate (MBTH) and potassium ferricyanide at pH 10.4 in 
aqueous medium to form an orange product that has a maximum absorption at 460 nm. Beer's law plot showed good 
correlation in the concentration range of 1.0−56.0 µg mL-1, with detection limit of 0.303 µg mL-1. Molar absorptivity for 
the above method was found to be 6.56×103 L mol-1 cm-1. All the measurements were carried out at 25 ± 1.0 °C, the 
formation constant (logKf) value of colored species is 9.48 and the standard free energy (G‡) is − 54.09 KJ mol-1. This 
method was applied successfully to determination of MD in tablets and the results were compared with the USP method. 
Common excipients used as additives in tablets do not interfere in the proposed method. The method is accurate, precise 
and highly reproducible, while being simple, cheap and less time consuming and hence can be suitably applied for routine 
analysis of MD in bulk and dosage forms. 
 





Methyldopa (MD), chemically known as α-methyl-3,4-
dihydroxyphenylalanine, is a catechol derivative 
(catecholamine) broadly prescribed to manage mild to 
moderate hypertension. In this context, methyldopa 
intrinsic chemical features may be explored through myriad 
analytical principles in order to optimize its detection. 
Amongst these features, the hydroxyl groups present in the 
molecule may undergo oxidation [1]. The official method 
reported in USP [2] describes a non-aqueous titration for the 
assay of methyldopa. Several analytical techniques have 
been cited in the literature for determination of methyldopa, 
either alone or in combination with other drugs, in bulk 
form, pharmaceutical formulations or biological fluids due 
to the wide use of this drug in numerous cardiac and 
circulatory diseases. These analytical methods include 
titrim etry [3,4], voltammetry [5-9], potentimetry [10,11], 
chemiluminescence [12,13], amperometry [14], capillary 
electrophoresis [15], HPLC with ultraviolet detector [16,7], 
HPLC with fluorescence detector [18], HPLC with 
electrochemical detection [19] and HPLC-electrospray 
tandem mass spectrometry (LC/MS/MS) [20]. Nuclear 
magnetic resonance (NMR) method for serum and 
pharmaceuticals was also reported [21]. However, mass-
selective detection and nmr are cost intensive and often not 
available for routine analysis. Some of these methods 
described above have disadvantages such as not simple for 
direct application to a large scale routine analysis, low 
sensitivity, long analysis times, and/or require expensive or 
sophisticated instruments. Also, titrimetric methods, which 
were indirect titration and based on reduction reactions and 
present disadvantages such as interferences of unsaturated 
organic compounds.  
Many spectrophotometric procedures have been proposed 
for the estimation of MD in pharmaceutical preparations 
including difference UV-spectrophotometric assay in the 
presence of germanium dioxide at 292 nm [22], Flow-
injection spectrophotometry [23-26], fluorimetry [27,28], 
kinetic spectrophotometry [29-31] and extractive 
spectrophotometry [32,33]. Moreover, the colorimetric 
method was the most widespread for estimation of MD in 
dosage form using I2 solution with acetate buffer of pH 4.7 
[4], 2-aminothiazole in alkaline medium [25], 
thiosemicarbazide in presence of ferric nitrate [26], 
NH4VO3 in the presence H3PO4 [34], (NH4)6Mo7O24.4H2O 
solution in H2SO4 [35], Fe(III)-ophenanthroline [36], 
barbituric acid [37], isoniazid in presence of N-
bromosuccinamide [38], diazotised sulphanilamide in the 
presence of molybdate [39], periodate in H2SO4 and 
determination of unreacted periodate by adding methylene 
blue and KI [40], iron (III) in the presence of 1,10-
phenanthroline and 2,2'-bipyridyl [41], p-nitroaniline in the 
presence of molybdate ions in acidic medium [42], Ce(IV) 
nitrate solution in H2SO4 [43], bromothymol blue in 
alkaline medium [44], sodium nitrite in an acid medium and 
further reacting the resultant nitroso derivative with sodium 
hydroxide [45], 2,2-diphenyil-picrylhydrazyl [46], 2,6-
dichloroquinone-4-chlorimide in acetate buffer and in water 
and ethanol solvents [47] and p-phenylenediamine in 
phosphate buffer at pH 7.4 [48]. 3-methylbenzothiazolin-2-
one hydrazone hydrochloride (MBTH) was used with 
(NH4)2SO4.Ce(SO4)2 in acetone or with K2Cr2O7 in 
methanol medium to determine MD. Beer's law was obeyed 
for 10 to 35 µg mL-1 and recoveries of methyldopa were 
98.7 to 101% [49]. Most of the spectrophotometric methods 
reported present some disadvantages such as require long 
waiting times [4,22,35-37,43], heating step [32,36,37,43] 
for the reaction development, instability of the colored 
 
Ashour S / Drug Anal. Res., v. 5, n. 1, p. 51-58, 2021 
 
52 
product at higher temperature [38,48], complex procedure 
[32,40,41,45], require non-aqueous media [10,32,33,47,49] 
or poor detection limit [34,48]. 
In this work, a validated colorimetric procedure for the 
determination of methyldopa in bulk and dosage form by 
the application of oxidative coupling reaction is described. 
This procedure is new, rapid, inexpensive, does not involve 
any pretreatment procedure or heating steps and has smaller 
sample consumption. The main advantage of this method is 







A Shimadzu UV-1650PC spectrophotometer (Japan) with 
1.0 cm quartz cells was used for all absorbance 
measurements. Spectra were automatically obtained by 
Shimadzu UV-1650PC system software. pH measurements 
and automatic potentiometric titration were made with 
Metrohm Compact Titrator Model 794 Basic Titrino 
(Switzerland) with glass pH electrode. 
 
Materials and chemicals 
 
Methyldopa, working standard, was obtained from S.A. 
Infinity (India). Its purity was found to be 99.5% according 
to the pharmacopeial method. Aldomet (Algorithm, 
Lebanone) and Dopegyt (Bahri Labs., Syria) tablets were 
purchased from local market, labeled to contain 250 mg of 
methyldopa per tablet. All chemicals used were of 
analytical grade. 3-methyl-2-benzothiazolinone hydrazone 
hydrochloride monohydrate (MBTH, Fluka) solution (0.01 
M), K3[Fe(CN)6] (BDH) solution (0.01 M) and Na2CO3 
solution (0.1 M) were prepared in bidistilled water. All the 
solutions were stable for one week at least when stored in 
the dark at 2–8 °C. 
 
Standard drug solutions 
 
Standard stock solution of MD (1.0 mg mL-1) was prepared 
by dissolving the appropriate weight of MD in 100 mL 
bidistilled water. Working standard solutions were then 
prepared by suitable dilution of the stock standard solution 




Job's method of continuous variation and molar ratio 
method were applied to study the stoichiometric ratio of the 
complex formed [50]. 1×10-3 M of MD and 1×10-2 M of 
MBTH solutions were used. In the molar ratio method a 
constant volume of MD solution was treated with varying 
volume of MBTH to obtain a ratio for the complex (0:1, 
0.1:0.9, 0.2:0.8,…, 1:0), while in Job's method, a series of 
MD-MBTH solutions was prepared to obtain a ratio for the 
complex (0:1, 0.1:0.9, 0.2:0.8,…, 1:0) where CMD+CMBTH 
=2.0×10-3 M. The absorbance of the resulting solutions was 
measured at max against the reagent blanks treated 
similarly. 
 
Validation of the proposed method 
 
The methods were validated in accordance with the 





To establish linearity of the proposed method, five separate 
series of solutions of MD (1.0–56.0 µg mL–1) were prepared 
from the stock standard solution and analyzed. Aliquots of 
0.01–0.56 mL solution of MD (1.0 mg mL-1) were piptted 
into a series of 10 mL calibrated volumetric flasks. In each 
flask, 0.6 mL of 0.01 M MBTH was added and kept aside 
for 5 min. 2.0 mL of 0.01 M K3[Fe(CN)6] and 0.2 mL of 0.1 
M Na2CO3 were added. The volume was made up to the 
mark with water at 25±1.0 °C. The contents of each flask 
were mixed well and the absorbance was measured at 460 
nm against a similar reagent blank within the stability 
period of 60 min after color development. The calibration 
graph of absorbance versus concentration of MD was 
constructed and described by the regression equation, 
A=mC+b (where A is the absorbance of a 1 cm layer, m is 
the slope, b is the intercept and C is the concentration of 




The sensitivity of the method was determined on the limit 
of detection (LOD) and limit of quantification (LOQ). LOD 
and LOQ of the drug assay were determined experimentally 
after getting the regression equation. LOD was expressed as 
the concentration of drug that generated a response to three 
times of the signal to-noise (S/N) ratio LOD=3.3×Sb/m and 
LOQ was 10 times of the S/N ratio LOQ=10×Sb/m (where 
Sb is the standard deviation of the intercept and m is the 




Repeatability was determined by using different levels of 
drug concentrations (same concentration levels taken in 
accuracy study), prepared from independent stock solutions 
and analyzed (n = 6) (Table 2). The percent relative 
standard deviation (%RSD) of the predicted concentrations 
from the regression equation was taken as precision (Table 
3). Precision studies were also carried out using the real 
samples of MD tablets in a similar way to standard solution 




To determine the accuracy of the proposed method, 
different levels of drug concentrations were prepared from 
independent stock solutions and analyzed (n=6). Accuracy 
was assessed as the percentage relative error and mean 
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percentage recovery. The percentage relative error 















The selectivity of the method was ascertained by analyzing 
standard drug in the presence of common excipients such as 
lactose, magnesium stearate, cellulose and silicon dioxide. 
For this purpose, a powder blend using typical tablet 





The robustness of an analytical procedure is a measure of 
its capacity to remain unaffected by small, but deliberate 
variations in method parameters and provides an indication 
of its reliability during normal usage. These condition 
changes included the concentration of the reagents in the 
reaction, measurement time and temperature. 
 
Procedure for formulations 
 
Twenty tablets containing MD were weighed and 
pulverized. Amount of the powder equivalent to 50 mg of 
MD was dissolved in a 25 mL of methanol and mixed for 
about 5 minutes and then filtered through Whatman filter 
paper number 40. The methanol was evaporated to about 
the dryness. The remaining portion of solution was diluted 
in a 50 mL volumetric flask to the volume with double 
distilled water to achieve a concentration of 1 mg mL-1. The 
general procedure was then followed in the concentration 
range mentioned above. 
 
Stability constant (Kf) and the standard free energy (G◦) 
of coloured species 
 
The stability constant (Kf) of the complex formed by MD 
with MBTH was determined by substituting the data of 
continuous variation in the equation (2) derived for 














=                                  (2) 
 
where A is the maximum observed absorbance and Am is the 
absorbance value when all the amount of drug is associated. 
CM is the mole concentration of drug at the maximum 
absorbance and n is the combination ratio of the ion-pair 
considered [54]. 
The standard free energy of the reaction product is related 
to the association or the formation constant by the equation 
(3), which was used to calculate Go [55]: 
 
G◦ = −2.303 RT log K                                                 (3) 
 
where G◦ is the free energy change of the complex, R is 
the gas constant 8.314 J k-1 mol-1, T is the temperature in 
Kelvin (k), K is the formation constant of complex. 
 




In order to establish experimental conditions, the effect of 
various parameters such as volumes of reagents, waiting 
time, order of addition of reagents and the stability of 
colored oxidative coupling product were studied at room 
temperature. The applicability of MBTH in combination 
with various oxidizing agents such as Fe(III), IO4-, 
(NH4)2S2O8 and Fe(CN)63- were examined. Preliminary 
investigations revealed that the cationic oxidant [Fe(III)] 
produced yellow color with MD and enhanced the final 
color. So, further investigations were carried out with 
anionic oxidants as they do not produce any color directly 
with MD. Fe(CN)63- was found to be superior because of its 
sensitivity over IO4-. Different buffers were used to 
determine the optimal pH for the reaction. 0.1 M Na2CO3 
with pH 10.4 gave the optimal pH required for the reaction. 
Of the different solvents tried, water was found to be the 
most suitable solvents. The color product was stable for 
further 60 min and was measured at 460 nm (Figure 1). 
 
 
Figure 1. Absorption spectra of (1) 0.5 mL of 1 mg mL-1 MD 
against distilled water, (2) MD (45 µg mL-1)-MBTH (0.6 mL of 
10-2 M) in the presence of Na2CO3 (0.2 mL of 0.1 M) and 
ferricyanide (2.0 mL of 10-2 M) system against reagent blank (3) 
vs. distilled water.  
 
Optimization of reaction conditions 
 
In order to establish experimental conditions of the 
developed color product, the effect of various parameters 
such as temperature, order of addition of reagents, 
concentration of reagents, reaction time and the stability of 
product were studied. 
 
Effect of temperature and order of addition 
 
The laboratory temperature (25  1.0 °C) was found to be 
optimal for all the experiments. Addition of MD, MBTH, 
Fe(CN)63- and Na2CO3 in that order gave maximum 
absorbance. Altering this order of addition (i.e. MD + 
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Fe(CN)63- + MBTH + Na2CO3) resulted in decrease in 
absorbance. 
 
Effect of reaction time 
 
The effect of time on the reaction of MD with MBTH and 
Fe(CN)63- in the presence of Na2CO3 is studied at max and 
laboratory ambient temperature (25 ± 1.0 °C). The reaction 
went to completion within 5 min and the absorbance of the 
chromogen remains stable for 60 min. Therefore, all 
measurements were carried out after 10 min of mixing of 
the reagents. 
 
Effect of reagent concentration 
 
The effect of MBTH, Fe(CN)63- and Na2CO3 concentrations 
were investigated. For maximum color development, 
solutions of 0.6 mL of 0.01 M MBTH, 2.0 mL of 0.01 M 
Fe(CN)63- and 0.2 mL of 0.1 M Na2CO3 pH 10.4 were found 
to be optimal of MD, since the absorbance was found to be 
maxima at the mentioned volumes, as shown in Figure 2. 
 
 
Figure 2. Effect of concentration of MBTH in the presence of 2.0 
mL of 10-2 M Fe(CN)63- and 0.2 mL of 0.1 M Na2CO3 pH 10.4, 
Fe(CN)63- in the presence of 0.6 mL of 10-2 M MBTH and 0.2 mL 
of 0.1 M Na2CO3 pH 10.4 and Na2CO3 pH 10.4 in the presence of 
0.6 mL of 10-2 M MBTH and 2.0 mL of 10-2 M Fe(CN)63- on the 
formation of colored oxidative coupling product MD-MBTH. 




The composition of MD-MBTH colored oxidative coupling 
product was determined by Job’s method using equimolar 
solution. The plot reached maximum at a mole fraction of 
0.33 and 0.5, indicating the formation of 1:2 and 1:1 
(MD:MBTH) colored product (Figure 3A). Also, the mole-
ratio method showed the formation of 1:1 and 1:2 
(MD:MBTH) colored product (Figure 3B). 
 
 
Figure 3. (A) Job's method of continuous variations of MD-MBTH 
product: CMD+CMBTH=2.0×10-3 M. (B) Mole-ratio method of MD-
MBTH product, CMD=5×10-4 M and CMBTH=125-1500 µM. 
 
When treated with ferricyanide, MBTH undergoes 
oxidation with loss of proton from nitrogen atom, and yields 
R' form or R" form. Also, MD is oxidized with loss of 
proton from the ring and coupling with the reagent R', or 
oxidized from enolic to ketonic form and coupling with the 
reagent R" to form the colored oxidative coupling product, 
as shown in Figure 4. 
 
 
Figure 4. Structure of MD and its reaction product with MBTH in 
alkaline medium. 
 
The stability constant (Kf) and the standard free energy 
(G) 
 
The stability constant (Kf) value of MD complex with 
MBTH was calculated from the continuous variation data 
using equation (2) and is tabulated in Table 1. The value of 
Gibbs free energy (G‡) of activation of the reaction 
product was determined using the equation 3, and its value 
was − 54.09 KJ mol-1. The negative value of the calculated 
free energy (ΔG‡) indicates the stability of the complex and 
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Table 1. Optical characteristics and regression parameters for MD 
by the proposed method. 
Parameter MD 
max (nm) 460 
Beer's law range (µg mL-1) 1.0–56.0 
Molar absorptivity (L mol-1 cm-1) 6.56×103 
Optimum photometric range  
(µg mL-1) 
5.0–40.0 
Logarithmic formation constant 
(log Kf) 
4.48 (1:1), 9.48 (1:2) 
LOD (µg mL-1) 0.303 
LOQ (µg mL-1) 1.000 
Sandell’s sensitivity (µg cm-2 per 
0.001 abs. unit) 
0.0329 
Regression equationa A=0.0274C+0.0188 
Correlation coefficient, r 0.9999 
a With respect to A=mC+b, where A is the absorbance and C is 
the concentration (µg mL–1). n=5. 
 
Validation of the proposed method 
 
The validity of the method for analysis of MD in its pure 
state and in formulations was examined by analyzing the 
samples using the proposed procedure. The precision and 
accuracy of the method were tested by analyzing six 
replicates of MD. The low values of RSD% indicate good 
precision and reproducibility of the method.  
 
Linearity, LOD and LOQ 
 
In order to test whether the colored oxidative coupling 
product formed in the above method adhere to Beer's law, 
the absorbance at appropriate length of a set of solutions 
containing varying amounts of MD and specified amounts 
of reagents (as given in the recommended procedure) were 
recorded against the corresponding reagent blank. A linear 
relationship was found between the absorbance at max and 
the concentration of MD in the range of 0.92–56.0 µg mL-
1, with LOD of 0.31 μg mL-1 and LOQ of 0.74 μg mL-1. 
Regression analysis of the Beer’s law plots reveals a good 
correlation (r > 0.999) and negligible intercept, as shown in 
Table 1. The high molar absorptivitie of the resulting 
colored oxidative coupling product indicates the high 
sensitivity of the method. Sandell's index represents the 
number of micrograms or nanograms of the determinant per 
millilitre of a solution having an absorbance of 0.001 for the 
cell path length of 1.0 cm and is a suitable parameter for 
expressing and comparing the sensitivity of developed 
spectrophotometric method. 
 
Intra- and interday accuracy and precision 
 
Repeatability was determined by using different levels of 
MD concentrations prepared from independent stock 
solutions and analyzed. Accuracy was assessed as the 
percentage relative error and mean percentage recovery. 
The percent relative standard deviation (RSD%) of the 
predicted concentrations from the regression equation was 
taken as precision. Five different concentrations of MD 
were analyzed in six replicates on the same day (intraday 
precision) and on four consecutive days (interday 
precision), as shown in Table 2. Precision studies were also 
carried out using the real samples of MD tablets in a similar 
way to standard solution to prove the useful of method.  
 
Table 2. Accuracy and precision of within and between run 













1.00 1.02 0.92 102.00 2.00 
5.00 5.03 0.83 100.66 0.66 
15.00 15.04 0.67 100.60 0.60 
25.00 25.12 0.54 100.60 0.60 
40.00 40.21 0.41 100.55 0.55 
Inter-day (n=6) 
1.00 1.01 0.98 101.00 1.00 
5.00 5.02 0.81 100.40 0.40 
15.00 15.05 0.70 100.33 0.33 
25.00 25.07 0.58 100.28 0.28 




The proposed method was found to be selective for the 
determination of MD in the presence of various tablet 
excipients. The recoveries were not affected by the 
excipients and the excipients blend did not show any 




Robustness was examined by evaluating the influence of 
small variation of method variables (Table 3) including 
MBTH, Fe(CN)63- and Na2CO3 volume, measurement time 
and temperature on the method suitability and sensitivity. 
The robustness of the method was studied by using five 
replicates at MD concentration level of 50 µg mL-1. The 
degree of reproducibility of the results obtained as a result 
of small deliberate variations in the method parameters has 
proven that the method is robust.  
 
Table 3. Results of robustness study of MD. 
Parameter variation Recovery%±SD 
No Change - 101.02±0.19 
Change in MBTH 0.01 M 
volume 
0.5 mL 98.89±0.21 
0.7 mL 100.02±0.16 
Change in K3[Fe(CN)6] 0.01 M 
volume 
1.9 mL 101.04±0.22 
2.1 mL 100.98±0.24 
Change in Na2CO3 0.1 M 
volume 
0.1 mL 98.76±0.17 
0.3 mL 100.01±0.18 
Change in measurement time 5.0min 100.92±0.11 
15 min 101.08±0.14 
Change in temperature 20 °C 100.94±0.15 
30 °C 101.09±0.12 
 
Application to the pharmaceutical dosage forms 
 
The proposed method was successfully applied for the 
determination of MD in tablet commercial formulations. 
The results given in Table 4 compared favorably with the 
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official method [2], at 95% confidence level, confirming the 
applicability of the proposed method for the determination 
of MD in pharmaceutical dosage forms (tablets). The results 
obtained were compared statistically [52]; the data of t and 
F ratios show no significant differences between the results 
of the proposed and the official methods, at a 95% 
confidence level. The RSD values obtained for the samples 
are between 0.6 and 0.8%, as shown in Table 4, indicating 
good precision of the method. The ingredients in the tablets 
such as starch, lactose, glucose, sodium chloride and 
titanium dioxide do not interfere with the assay procedures. 
Therefore, the spectrophotometric method for 
determination of MD in pharmaceutical formulations 
reported in this paper is precise, accurate, and suitable for 
use in routine analysis. 
 



















aFive independent analyses. At 95% confidence level t-critical is 




In the present study, an oxidative coupling reaction for the 
colorimetric determination of methyldopa in commercial 
pharmaceutical preparations is described. Proposed method 
makes use of simple reagents, which an ordinary analytical 
laboratory can afford. The sample recoveries from all 
formulations were in good agreement with their respective 
label claims, which suggested non-interference of 
formulations excipients in the estimation. Method is highly 
sensitive to permit determination even down to 0.303 µg 
mL-1. This method is simple, rapid, precise, accurate and 
not time-consuming technique such as GC, HPLC and etc. 
Therefore, this approach could be considered for the 
analysis of methyldopa in bulk and tablet dosage form. 
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